Skip to contentA
Arcus Biosciences, Inc.
A
RCUSArcus Biosciences, Inc. Q2 2026 · 10-Q
Revenue$33.00M$33.00M+312.5% vs Q2 2025 Net Income-$91.00M-$91.00M— vs Q2 2025 EPS Diluted-$0.72-$0.72— vs Q2 2025 Operating Income-$96,000,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$119,000,000N/M Margins · derivedOperating margin-290.9%−190.9 pt vs Q2 2025
Net margin-275.8%−275.8 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end